A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger
Key takeaways
- A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger Jabran Kundi Fri, July 3, 2026 at 8:41 PM GMT+7 2 min read MLYS Mineralys Therapeutics Inc.
- Earlier on June 2, MLYS revised its agreement with Tanabe Pharma to gain full worldwide rights to lorundrostat without having to pay future royalties.
- (NASDAQ:MLYS) is a biopharmaceutical company that develops medicines to target diseases driven by dysregulated aldosterone.
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger Jabran Kundi Fri, July 3, 2026 at 8:41 PM GMT+7 2 min read MLYS Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 8 Hidden Multibagger Stocks to Buy Now. During the last few trading sessions, Mineralys Therapeutics Inc. (NASDAQ:MLYS) has seen positive momentum. On June 4, Goldman Sachs analyst Richard Law reiterated a Buy rating on the stock and assigned a target price of $42.
Earlier on June 2, MLYS revised its agreement with Tanabe Pharma to gain full worldwide rights to lorundrostat without having to pay future royalties. Under this amendment, the company agreed to pay Tanabe a $200 million upfront cash payment and could make additional payments of up to $365 million if certain commercial targets are achieved. Moreover, the company secured a loan of up to $500 million from funds managed by Pharmakon Advisors. The financing will be provided in stages, with access to additional funds tied to the FDA approval of lorundrostat and the achievement of certain sales milestones. This loan will provide capital to support the company's growth and commercialization plans. However, it also increases MLYS's debt obligations, which could limit the company's financial flexibility.
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is a biopharmaceutical company that develops medicines to target diseases driven by dysregulated aldosterone. Its primary drug candidate is lorundrostat, which is used for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.